Fibroblast Growth Factor-23

Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism: Seventh Edition

Volumn , Issue , 2009, Pages 112-116

  White, Kenneth E ^a   Econs, Michael J ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Fibroblast growth factor receptor; Fibroblast growth factor 23; Hyperphosphatemia; Hypophosphatemia; Klotho; Phosphate; Phosphate metabolism; Vitamin D

Indexed keywords

EID: 76649109814     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470623992.ch23     Document Type: Chapter

References (42)

1. Consortium ADHR 2000 Autosomal dominant hypophosphatae-mic rickets is associated with mutations in FGF23. Nat Genet 26:345-348.
2. Riminucci M, Collins MT, Fedarko NS, Cherman N, Corsi A, White KE, Waguespack S, Gupta A, Hannon T, Econs MJ, Bianco P. Gehron Robey P 2003 FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 112:683-692.
3. Liu S, Guo R, Simpson LG, Xiao ZS, Burnham CE, Quarles LD 2003 Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem 278:37419-37426.
4. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T 2001 Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 98:6500-6505.
5. White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM, Econs MJ 2001 Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 60:2079-2086.
6. Larsson T, Marsell R, Schipani E. Ohlsson C, Ljunggren O, Tenenhouse HS, Juppner H, Jonsson KB 2004 Transgenic mice expressing fibroblast growth factor 23 under the control of the alphal(I) collagen promoter exhibit growth retardation, osteoma-lacia, and disturbed phosphate homeostasis. Endocrinology 145:3087-3094.
7. Burnett SM, Gunawardene SC, Bringhurst FR, Juppner H, Lee H, Finkelstein JS 2006 Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res 21:1187-1196.
8. Perwad F, Azam N, Zhang MY, Yamashita T, Tenenhouse HS, Portale AA 2005 Dietary and serum phosphorus regulate fibro-blast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice. Endocrinology 146:5358-5364.
9. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T 2004 FGF-23 is a potent regulator of vitamin D metabolism and phosphate ho-meostasis. J Bone Miner Res 19:429-135.
10. Tsujikawa H, Kurotaki Y, Fujimori T, Fukuda K, Nabeshima Y 2003 Klotho, a gene related to a syndrome resembling human premature aging, functions in a negative regulatory circuit of vi-tamin D endocrine system. Mol Endocrinol 17:2393-2403.
11. Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka K, Yamashita T 2004 Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 113:561-568.
12. Sitara D, Razzaque MS, Hesse M, Yoganathan S, Taguchi T, Er-ben RG, Jap H, Lanske B 2004 Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skel-etogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol 23:421-432.
13. Segawa H, Yamanaka S, Ohno Y, Onitsuka A, Shiozawa K, Aranami F, Furutani J, Tomoe Y, Ito M, Kuwahata M, Tatsumi S, Imura A, Nabeshima Y, Miyamoto KI 2006 Correlation between hyperphosphatemia and type II Na/Pi cotransporter activity in klotho mice. Am J Physiol Renal Physiol 292:F769-F779.
14. Li SA, Watanabe M, Yamada H, Nagai A, Kinuta M, Takei K 2004 Immunohistochemical localization of Klotho protein in brain, kidney, and reproductive organs of mice. Cell Struct Funct 29:91-99.
15. Matsumura Y, Aizawa H, Shiraki-Iida T, Nagai R, Kuro-o M, Nabeshima Y 1998 Identification of the human klotho gene and its two transcripts encoding membrane and secreted klotho protein. Biochem Biophys Res Commun 242:626-630.
16. Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, Fujita T, Fukumoto S, Yamashita T 2006 Klotho con-verts canonical FGF receptor into a specific receptor for FGF23. Nature 444:770-774.
17. Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosen-blatt KP, Baum MG, Schiavi S, Hu MC, Moe OW, Kuro-o M 2006 Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 281:6120-6123.
18. Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ. Lavigne J, Juppner H 2003 Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 348:1656-1663.
19. Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K. Tajima T, Takeuchi Y, Fujita T, Nakahara K, Yamashita T, Fu-kumoto S 2002 Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 87:4957-4960.
20. Khosravi A, Cutler CM, Kelly MH, Chang R, Royal RE, Sherry RM, Wodajo FM, Fedarko NS, Collins MT 2007 Determination of the elimination half-life of fibroblast growth factor-23. J Clin En-docrinol Metab 92:2374-2377.
21. Takeuchi Y, Suzuki H, Ogura S, Imai R, Yamazaki Y, Yamashita T, Miyamoto Y, Okazaki H, Nakamura K, Nakahara K, Fukumoto S, Fujita T 2004 Venous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia. J Clin Endocrinol Metab 89:3979-3982.
22. Econs MJ, McEnery PT 1997 Autosomal dominant hypophospha-temic rickets/osteomalacia: Clinical characterization of a novel re-nal phosphate-wasting disorder. J Clin Endocrinol Metab 82:674-681.
23. White KE, Jonsson KB, Carn G, Hampson G, Spector TD, Mannstadt M, Lorenz-Depiereux B, Miyauchi A, Yang IM, Ljung-gren O, Meitinger T, Strom TM, Juppner H, Econs MJ 2001 The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phos-phate wasting. J Clin Endocrinol Metab 86:497-500.
24. Ryan EA, Reiss E 1984 Oncogenous osteomalacia. Review of the world literature of 42 cases and report of two new cases. Am J Med 77:501-512.
25. Hyp Consortium 1995 A gene (PEX) with homologies to endo-peptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium. Nat Genet 11:130-136.
26. Beck L, Soumounou Y, Martel J, Krishnamurthy G, Gauthier C, Goodyer CG, Tenenhouse HS 1997 Pex/PEX tissue distribution and evidence for a deletion in the 3' region of the Pex gene in X-linked hypophosphatemic mice. J Clin Invest 99:1200-1209.
27. Feng JQ, Ward LM, Liu S, Lu Y, Xie Y, Yuan B, Yu X. Rauch F, Davis SI, Zhang S, Rios H, Drezner MK, Quartes LD, Bonewald LF, White KE 2006 Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 38:1310-1315.
28. Lorenz-Depiereux B, Bastepe M, Benet-Pages A, Amyere M, Wa-genstaller J, Muller-Barth Ü, Badenhoop K, Kaiser SM, Rittmas-ter RS, Shlossberg AH, Olivares JL, Loris C, Ramos FJ, Glorieux F, Vikkula M, Juppner H, Strom TM 2006 DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet 38:1248-1250.
29. Zeger MD, Adkins D, Fordham LA, White KE, Schoenau E. Rauch F, Loechner KJ 2007 Hypophosphatemic rickets in opsis-modysplasia. J Pediatr Endocrinol Metab 20:79-86.
30. White KE, Cabral JM, Davis SI, Fishburn T, Evans WE, Ichikawa S, Fields J, Yu X, Shaw NJ, McLellan NJ, McKeown C, Fitzpatrick D, Yu K, Ornitz DM, Econs MJ 2005 Mutations that cause osteo-glophonic dysplasia define novel roles for FGFR1 in bone elon-gation. Am J Hum Genet 76:361-367.
31. Hoffman WH, Jueppner HW, Deyoung BR, O'Dorisio MS, Given KS 2005 Elevated fibroblast growth factor-23 in hypophospha-temic linear nevus sebaceous syndrome. Am J Med Genet A 134:233-236.
32. Prince MJ, Schaeffer PC, Goldsmith RS, Chausmer AB 1982 Hy-perphosphatemic tumoral calcinosis: Association with elevation of serum 1,25-dihydroxycholecalciferol concentrations. Ann Intern Med 96:586-591.
33. Frishberg Y, Topaz O, Bergman R, Behar D, Fisher D, Gordon D, Richard G, Sprecher E 2005 Identification of a recurrent mutation in GALNT3 demonstrates that hyperostosis-hyperphosphatemia syndrome and familial tumoral calcinosis are allelic disorders. J Mol Med 83:33-38.
34. Ichikawa S, Guigonis V, Imel EA, Courouble M, Heissat S, Hen-ley JD, Sorenson AH, Petit B, Lienhardt A, Econs MJ 2007 Novel GALNT3 mutations causing hyperostosis-hyperphosphatemia syndrome result in low intact fibroblast growth factor 23 concen-trations. J Clin Endocrinol Metab 92:1943-1947.
35. Topaz O, Shurman DL, Bergman R, Indelman M, Ratajczak P, Mizrachi M, Khamaysi Z, Behar D, Petronius D, Friedman V, Zelikovic I, Raimer S, Metzker A, Richard G, Sprecher E 2004 Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nat Genet 36:579-581.
36. Garringer HJ, Fisher C, Larsson TE, Davis SI, Koller DL, Cullen MJ, Draman MS, Conlon N, Jain A, Fedarko NS, Dasgupta B, White KE 2006 The role of mutant UDP-N-acetyl-alpha-D-galactosamine-polypeptide N-acetylgalactosaminyltransferase 3 in regulating serum intact fibroblast growth factor 23 and matrix ex-tracellular phosphoglycoprotein in heritable tumoral calcinosis. J Clin Endocrinol Metab 91:4037-4042.
37. Frishberg Y, Ito N, Rinat C, Yamazaki Y, Feinstein S, Urakawa I, Navon-Elkan P. Becker-Cohen R, Yamashita T, Araya K, Igarashi T, Fujita T, Fukumoto S 2007 Hyperostosis-hyperphosphatemia syndrome: A congenital disorder of O-glycosylation associated with augmented processing of fibroblast growth factor 23. J Bone Miner Res 22:235-242.
38. Benet-Pages A. Orlik P, Strom TM, Lorenz-Depiereux B 2005 An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet 14:385-390.
39. Larsson T. Yu X, Davis SI, Draman MS, Mooney SD, Cullen MJ, White KE 2005 A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis. J Clin Endocrinol Metab 90:2424-2427.
40. Araya K, Fukumoto S, Backenroth R, Takeuchi Y, Nakayama K, Ito N, Yoshii N, Yamazaki Y, Yamashita T, Silver J, Igarashi T, Fujita T 2005 A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis. J Clin Endocrinol Metab 90:5523-5527.
41. Ichikawa S, Imel EA, Kreiter ML, Yu X, Mackenzie DS, Sorenson AH, Goetz R. Mohammadi M, White KE, Econs MJ 2007 A ho-mozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J Clin Invest 117:2684-2691.
42. Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, Ritz E, Kronenberg F, Kuen E, Konig P, Kraatz G, Mann JF, Muller GA, Kohler H, Riegler P 2007 Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: The Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 18:2600-2608.